EA Pharma Co., Ltd.
EA Pharma Co., Ltd. (President & CEO, Yuji Matsue; Headquarters, Tokyo, Japan) (hereinafter “EA Pharma”), a subsidiary of Eisai Co., Ltd. for the gastrointestinal disease area, announced today that EA Pharma obtained the “First-class Marketing License for Medical Devices” from Tokyo Metropolitan Government.
With the above license according to Article 23-2 (1) of The Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, EA Pharma is now qualified to manufacture and market medical devices in addition to pharmaceuticals.
Starting with “Eleview”, an agent to lift up the lesions in endoscopic mucosal resection and endoscopic submucosal dissection, which is in-licensed from Cosmo Technologies Ltd. (please see our New Release March 22, 2018), EA Pharma strives to make a contribution in the medical device field, also, targeting endoscopy, perisurgical, stenosis relief and others in the gastrointestinal area.
To meet the various needs of patients, their families and medical practitioners in the gastrointestinal disease area, EA Pharma aims to provide a wide range of solutions and create new medical value through expansion of pharmaceutical and medical device business in the gastrointestinal disease area.
【Outline of the First-class Marketing License for Medical Devices】
| Company site name | ：EA Pharma Co., Ltd. (headquarters) |
| Date of issuance | ： March 30, 2018 |
| Classification of license | ： First-class Marketing License for Medical Devices |
End
| More information |
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years’ history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/en/